Entry Point Capital, LLC 4 D Molecular Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 7,265 shares of FDMT stock, worth $60,662. This represents 0.22% of its overall portfolio holdings.
Number of Shares
7,265Holding current value
$60,662% of portfolio
0.22%Shares
1 transactions
Others Institutions Holding FDMT
# of Institutions
150Shares Held
57.2MCall Options Held
55.6KPut Options Held
167K-
Ra Capital Management, L.P. Boston, MA5.1MShares$42.6 Million1.61% of portfolio
-
Black Rock Inc. New York, NY4.9MShares$40.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$36.7 Million10.13% of portfolio
-
Goldman Sachs Group Inc New York, NY4.13MShares$34.5 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.06MShares$33.9 Million2.8% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $270M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...